Published: October 19, 2015

Recent studies show promising results with the use of enzalutamide in patients who have metastatic prostate cancer that has progressed while on ADT, whether it is given before or after chemotherapy. Enzalutamide, in both settings, as compared with placebo, significantly extended survival with delays in disease progression, improved patient-reported quality of life and had a favourable adverse event profile.

Published: July 24, 2015

Research conducted by Canadian Cancer Trials Group at Queen’s University has provided new information regarding the use of radiotherapy in the treatment of breast cancer.